Meta-analysis
Sep 2026
Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA)
Abstract Designing phase III oncology trials to demonstrate overall survival (OS) superiority may be challenging due to sample size, follow-up time, resources, and costs as compared to trials evaluating intermediate endpoints, which may or may not be reliable surrogates of OS. In this study, we investigate at scale the...
A. Sherry, N. Meimoun, A. Miller et al.
· The Oncologist · 0 citations